Skip to main content

Full text of "USPTO Patents Application 09848616"

See other formats


SEBBEL et al 
Appl. No. 09/848,616 



Amendments 

In the Claims: 

Claims 1-85 (Cancelled). 

Claim 86 (Previously presented). A composition comprising: 

(a) a non-natural molecular scaffold comprising: 

(i) a virus-like particle that is a dimer or a multimer of a 
polypeptide comprising, as a core particle, a polypeptide 
having the amino acid sequence of SEQ ID NO: 158, 
modified such that the cysteine residues at positions 48 and 
1 10 of SEQ ID NO: 158 (corresponding to positions 48 and 
1 07 of SEQ ID NO: 1 34) are either deleted or substituted with 
another amino acid, or a sequence having at least 90% 
sequence identity to said polypeptide sequence and in which 
the cysteine residues at positions 48 and 110 of SEQ ED 
NO: 1 58 are either deleted or substituted with another amino 
acid; and 

(ii) an organizer comprising at least one first attachment site, 
wherein said organizer is connected to said core particle by at 
least one covalent bond; and 

(b) an antigen or antigenic determinant with at least one second 
attachment site, said second attachment site being selected from the 
group consisting of: 



- 4 - SEBBEL et al 

Appl. No. 09/848,616 

(i) an attachment site not naturally occurring with said antigen or 
antigenic determinant; and 

(ii) an attachment site naturally occurring with said antigen or 
antigenic determinant, 

wherein said second attachment site is capable of association through at least one non- 
peptide bond to said first attachment site; and 

wherein said antigen or antigenic determinant and said scaffold interact through said 
association to form an ordered and repetitive antigen array. 

Claims 87-89 (Cancelled). 

Claim 90 (Currently amended). The composition of any on e of claims 86 89 claim 
86 , wherein said organizer is a polypeptide or residue thereof; and wherein said second 
attachment site is a polypeptide or residue thereof. 

Claim 91 (Currently amended). The composition of any on e of claims 86 89 claim 
86 , wherein said first and/or said second attachment sites comprise: 

(a) an antigen and an antibody or antibody fragment thereto; 

(b) biotin and avidin; 

(c) strepavidin and biotin; 

(d) a receptor and its ligand; 

(e) a ligand-binding protein and its ligand; 

(f) interacting leucine zipper polypeptides; 



- 5 - SEBBEL et al 

Appl. No. 09/848,616 

(g) an amino group and a chemical group reactive thereto; 

(h) a carboxyl group and a chemical group reactive thereto; 

(i) a sulfhydryl group and a chemical group reactive thereto; or 
(j) a combination thereof. 

Claim 92 (Previously presented). The composition of claim 91, wherein said first 
attachment site is an amino group and said second attachment site is a sulfhydryl group. 

Claim 93 (Currently amended). The composition of any on e of claims 86 89 claim 
86 . wherein said antigen or antigenic determinant is selected from the group consisting 
of: 

(a) an antigen suited to induce an immune response against bacteria; 

(b) an antigen suited to induce an immune response against viruses; 

(c) an antigen suited to induce an immune response against parasites; 

(d) an antigen suited to induce an immune response against cancer cells; 

(e) an antigen suited to induce an immune response against allergens; 

(f) an antigen suited to induce an immune response in a farm animals; 
and 

(g) a protein suited to induce an immune response in a pet. 

Claim 94 (Previously presented). The composition of claim 93, wherein the antigen 
or antigenic determinant is a protein, polypeptide, or a fragment thereof. 



-6- 



SEBBEL et al 
Appl. No. 09/848,616 



Claim 95 (Previously presented). The composition of claim 93, wherein said antigen 
or antigenic determinant induces an immune response against one or more allergens. 

Claim 96 (Previously presented). The composition of claim 93, wherein said antigen 
or antigenic determinant is selected from the group consisting of: 

(a) a recombinant protein of HIV; 

(b) a recombinant protein of Influenza virus; 

(c) a recombinant protein of Hepatitis C virus; 

(d) a recombinant protein of Toxoplasma; 

(e) a recombinant protein of Plasmodium falciparum; 

(f) a recombinant protein of Plasmodium vivax; 

(g) a recombinant protein of Plasmodium ovale; 

(h) a recombinant protein of Plasmodium malariae; 

(i) a recombinant protein of breast cancer cells; 
(j) a recombinant protein of kidney cancer cells; 
(k) a recombinant protein of prostate cancer cells; 
(1) a recombinant protein of skin cancer cells; 
(m) a recombinant protein of brain cancer cells; 
(n) a recombinant protein of leukemia cells; 

(o) a recombinant protein of bee sting allergy; 
(p) a recombinant protein of nut allergy; 
(q) a recombinant protein of food allergies; 



-7- 



SEBBEL et al 
Appl.No. 09/848,616 



(r) a recombinant protein of asthma; and 
(s) a recombinant protein of Chlamydia. 

Claim 97 (Currently amended). A pharmaceutical composition comprising the 
composition of any on e of claims 86 89 claim 86 , and a pharmaceutically acceptable carrier. 

Claim 98 (Currently amended). A vaccine composition comprising the composition 
of any on e of claims 86 89 claim 86 . 

Claim 99 (Previously presented). The vaccine composition of claim 98, further 
comprising at least one adjuvant. 

Claim 100 (Previously presented). A method of immunizing, comprising 
administering to a subject the vaccine composition of claim 98. 

Claim 101 (Previously presented). The method of claim 100, wherein said 
administering produces an immune response. 

Claim 102 (Previously presented). The method of claim 101, wherein said 
administering produces a humoral immune response. 

Claim 103 (Previously presented). The method of claim 101, wherein said 
administering produces a cellular immune response. 



-8- 



SEBBEL et al, 
Appl. No. 09/848,616 



Claim 104 (Previously presented). The method of claim 101, wherein said 
administering produces a humoral immune response and a cellular immune response. 

Claim 105 (Previously presented). The method of claim 101, wherein said 
administering produces a protective immune response. 

Claim 1 06 (Currently amended). A method of making the composition of any on e of 
claims 86 89 claim 86 , comprising combining said non-natural molecular scaffold and said 
antigen or antigenic determinant, wherein said non-natural molecular scaffold and said 
antigen or antigenic determinant interact to form an antigen array. 

Claim 107 (Previously presented). The method of claim 106, wherein said antigen 
array is ordered and/or repetitive. 

Claim 108 (Currently amended). A method of immunizing, comprising 
administering the composition of any on e of claims 86 - 89 claim 86 . or the vaccine 
composition of claim 98, to a subject, wherein said administering produces a Th2 response 
that is specific for said antigen or antigenic determinant. 

Claim 109 (Previously presented). The method of claim 108, wherein antibodies 
specific for said antigen or antigenic determinant of a subtype corresponding to the Th2 
subtype are induced in the subject. 



- 9 - SEBBEL et al. 

Appl. No. 09/848,616 

Claim 110 (Previously presented). The method of claim 108, wherein the subject 
does not generate a Thl response that is specific for said antigen or antigenic determinant.